Search bioRxiv⌕ Search

Biology subjects

Brajkovic, M.

Publications and source records attributed to Brajkovic, M..

2 recordsLinked to original sources

On the determinants of residence times and dissociation mechanisms of complexes of interleukin-13 with its low and high affinity receptors

Interleukin-13 (IL-13) is an immunomodulatory cell signaling cytokine that has been implicated in neurodegenerative disease and chronic inflammation. IL-13 binds to its low and high affinity receptors, IL-13 receptor 1 (IL-13R1) and IL-13 receptor 2 (IL-13R2), respectively, with residence times that vary accordingly. As the binding kinetics of the cytokine-receptor complexes influence cellular responses, we employed the molecular dynamics (MD) simulation-based{tau} -random acceleration molecular dynamics method ({tau}RAMD) to compute relative residence times for wild-type (WT) IL-13 and 19 IL-13 mutants to the two receptors. Comparison with experimental kinetic data shows that the{tau} RAMD computations capture the trends in residence times. Analysis of simulated dissociation trajectories of the cytokine-receptor complexes reveals two distinct dissociation pathways of IL-13 from each of the receptors. This study thus pinpoints key determinants of the interaction of IL-13 with its receptors which could be targeted for therapeutic design. Statement of SignificanceCytokines are regulatory proteins that bind to cell surface receptors and thereby send signals to the cellular interior. Interleukin-13 (IL-13) is a cytokine that has a low and a high affinity receptor. It has important physiological roles, and its deregulation is involved in diseases such as atopic dermatitis and asthma. We employed a molecular dynamics simulation-based method to compute the effects of changes in the sequence of IL-13 on the lifetimes of complexes of IL-13 and its receptors. Comparison with experiments supports the validity of the computational approach and analysis of the simulations reveals two distinct ways in which IL-13 dissociates from each receptor. These results thus provide a map for targeting IL-13 - receptor interactions for the design of therapeutics.

biophysics↗

Targeting dendritic cells with RNA-loaded nanoparticles grafted with short peptides

Nanoparticles encapsulating therapeutic RNA have emerged as a transformative strategy in precision medicine, capable of mobilizing the immune system to induce specific responses, ranging from immune tolerance to fighting tumors. However, most current preclinical and clinical efforts rely on non-targeted delivery systems, limiting their safety, therapeutic efficacy, and selectivity. To enhance the therapeutic index of RNA-based therapeutic systems for immunomodulatory purposes, we report on the design of a novel Clec9A-targeted polymeric nanoparticle, aimed at selectively engaging dendritic cells responsible for antigen presentation. We began by evaluating in silico the binding potential of the previously reported 12-amino-acid WH peptide, known for its high affinity to mouse Clec9A, the human ortholog. Using computational tools, we designed and screened truncated variants of the peptide and identified promising candidates with retained or enhanced binding capacity to human Clec9A. These optimized short peptides were synthesized and covalently conjugated to our proprietary poly(beta amino ester) (pBAE) polymers. We evaluated the impact of conjugation site, comparing terminal versus lateral chain attachment on receptor targeting and confirmed in vitro that peptide orientation significantly influences binding efficiency. Additionally, we computationally generated and validated shorter mutant peptide variants with improved Clec9A affinity over the original sequences. Our findings demonstrate that rationally engineered short peptides, when site-specifically conjugated to pBAE polymers, can provide high-affinity, selective targeting of dendritic cells via Clec9A. This strategy lays the groundwork for the next generation of targeted RNA-based immunotherapeutics, offering improved selectivity, immune activation, and therapeutic potential. Graphical abstractSchematic representation of the workflow used in this work. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/686747v1_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@17f2d4eorg.highwire.dtl.DTLVardef@779825org.highwire.dtl.DTLVardef@1a5ded2org.highwire.dtl.DTLVardef@c7cb96_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗